Trastuzumab-Dkst, also known by its brand name Ogivri, is a medication used in the treatment of certain types of cancer. Specifically, it is a biosimilar to trastuzumab, a monoclonal antibody that targets the HER2 protein, which is overexpressed in some breast and gastric cancers. By binding to HER2, trastuzumab-Dkst inhibits the growth of cancer cells and can help slow or stop the progression of the disease.
As a medical professional, it is important to understand the indications for trastuzumab-Dkst and how it should be administered. This medication is typically used in combination with other chemotherapy drugs for the treatment of HER2-positive breast cancer or metastatic gastric cancer. It is given intravenously and the dosage and frequency will depend on the specific type and stage of cancer being treated.
Like any medication, trastuzumab-Dkst can cause side effects. Common side effects may include nausea, vomiting, diarrhea, fatigue, and infusion reactions. It is important to monitor patients closely for any signs of allergic reactions or other serious side effects.
Overall, trastuzumab-Dkst is an important treatment option for patients with HER2-positive cancers. It has been shown to improve outcomes and quality of life for many patients. As a medical professional, it is important to stay informed about the latest research and guidelines regarding the use of trastuzumab-Dkst in order to provide the best possible care for your patients.
EN 
ES 
FR 
PT 
ZH